Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors

Bone Marrow Transplantation

Volumn 17, Issue 5, 1996, Pages 819-824

  Hamblin, M ^a   Marsh, J C W ^a,d   Lawler, M ^b   McCann, S R ^b   Wickham, N ^a   Dunlop, L ^a   Ball, S ^a   Davies, E G ^a   Hale, G ^c   Waldmann, H ^c   Gordon Smith, E C ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b ST JAMES S HOSPITAL   (Ireland)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Aplastic anaemia; Campath 1G; Chimaerism

Indexed keywords

ALEMTUZUMAB; ANTIHISTAMINIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FANSIDAR; HYDROCORTISONE; MESNA; PENTOXIFYLLINE; PETHIDINE; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CHIMERA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; FEVER; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HLA MATCHING; HUMAN; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; LIVER DISEASE; MALE; MULTICENTER STUDY; NEUTROPHIL; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RIGOR; SIBLING; SUBCUTANEOUS DRUG ADMINISTRATION; TACHYCARDIA; TANDEM REPEAT;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; ANTIBODIES, MONOCLONAL; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CHIMERA; CYTOMEGALOVIRUS INFECTIONS; FAMILY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVING DONORS; MALE; MIDDLE AGED; PNEUMONIA, VIRAL; POLYMERASE CHAIN REACTION;

EID: 0029948935     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Bacigalupo A, Hows J, Gluckman E et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA Working Party. Br J Haematol 1988; 70: 177-182.
2. Gluckman E, Socie G, Devergie A et al. Bone marrow transplantation in 107 patients with severe aplastic anaemia using cyclophosphamide and thoraco-abdominal irradiation for conditioning: long-term follow-up. Blood 1991; 78: 2451-2455.
3. Hows JM, Marsh JCW, Yin JL et al. Bone marrow transplantation for severe aplastic anaemia using cyclosporin: long-term follow-up. Bone Marrow Transplant 1989; 4: 11-16.
4. Paquette RL, Tebyani N, Frane M et al. Long-term outcome of aplastic anaemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation. Blood 1995; 85: 283-290.
5. Storb R, Etzioni R, Anasetti C et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants with aplastic anaemia. Blood 1994; 84: 941-949.
6. Young NS, Barrett AJ. The treatment of severe acquired aplastic anaemia. Blood 1995; 85: 3367-3377.
7. Gluckman E, Horowitz MM, Champlin RE et al. Bone marrow transplantation for severe aplastic anaemia: influence of conditioning and graft-versus-host disease prophylaxis regimes on outcome. Blood 1992; 79: 269-275.
8. Socie G, Henry-Amar M, Cosset JM et al. Increased incidence of solid tumours after bone marrow transplantation for severe aplastic anaemia. Blood 1991; 78: 277-279.
9. Storb R, Doney KC, Thomas ED et al. Marrow transplantation with or without donor buffy coats for 65 transfused aplastic patients. Blood 1982; 59: 236-241.
10. Storb R, Prentice RL, Sullivan KM et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anaemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983; 98: 461-466.
11. Hale G, Bright S, Chumbley G et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983; 62: 873-882.
12. Hale G, Waldmann H. Campath-1 monoclonal antibody in bone marrow transplantation. J Haematother 1994; 3: 15-31.
13. Jacobs P, Wooa L, Fullard L et al. T cell depletion by exposure to Campath 1G in vitro prevents graft-versus-host disease. Bone Marrow Transplant 1994; 13: 763-769.
14. Willemze R, Richel DJ, Falkenburg JHP et al. In vivo use of Campath 1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation. Bone Marrow Transplant 1992; 9: 255-261.
15. Naparstek E, Or R, Nagler A et al. T cell depleted allogeneic bone marrow transplants for acute leukaemia using Campath-1 antibodies and post transplant administration of donor peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995; 89: 506-515.
16. Champlin RE, Horowitz MM, van Bekkum DW et al. Graft failure following bone marrow transplantation for severe aplastic anaemia: risk factors and treatment results. Blood 1989; 73: 606-613.
17. Or R, Naparstek, Engelhard D et al. Bone marrow transplantation (BMT) using T cell depletion (TCD) vs no T cell depletion in patients with severe aplastic anaemia (SAA). 10 years experience. Blood 1991; 78 (Suppl. 1): 228a.
18. Philpott NJ, Marsh JCW, Kumaran TO et al. Successful bone marrow transplant for Fanconi anaemia in transformation. Bone Marrow Transplant 1994; 14: 151-153.
19. Lawler M, Humphries P, McCann SR. Evaluation of mixed chimerism by in vitro amplification of dinucleotide repeat sequences using the polymerase chain reaction. Blood 1991; 77: 2504-2514.
20. Hill RS, Peterson FB, Storb R et al. Mixed haematological chimaerism after allogeneic marrow transplantation for severe aplastic anaemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood 1986; 67: 811-816.
21. Spitzer TR, Himoe E, Cottler-Fox M et al. Long-term stable mixed chimaerism following allogeneic marrow transplantation for severe aplastic anaemia. Br J Haematol 1990; 76: 146-154.
22. Weitzel JN, Hows JM, Jeffreys A et al. Use of hypervariable minisatellite DNA probe (33.15) for evaluating engraftment two or more years after bone marrow transplantation for severe aplastic anaemia. Br J Haematol 1988; 70: 91-97.
23. Keable H, Bourhis JH, Brison O et al. Long-term study of chimerism in bone marrow transplantation recipients for severe aplastic anaemia. Br J Haematol 1989; 71: 525-533.
24. Lawler M, McCann SR, Ljungman P et al. Mixed chimerism may predict graft rejection in patients transplanted for severe aplastic anaemia. J Cell Biochem 1994; (Suppl. 18b): 504 abstr.
25. Arnold R, Bunjes D, Wiesneth M et al. In vitro and in vivo depletion of T cells. Bone Marrow Transplant 1993; 12 (Suppl. 3): 11-12.
26. Hale G, Waldmann H for Campath users. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant 1994; 13: 597-616.
27. Gilleece MH, Dexter TM. Effect of Campath 1H antibody on human haematopoietic progenitors in vitro. Blood 1993; 82. 807-812.
28. Hale G, Waldmann H. Report of Campath users meeting. Bone Marrow Transplant 1995 (in preparation).